- Regulation of promotion and advertisement of drug related information
- Fast-Track assessment of variations (Amendments) and CTD dossier applications
- Unauthorized Chinese Pill Tablets on the Market
- WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa
- Implementation of the National Drug Policy and Authority (fees) Regulations 2022
- National Drug Authority statement on conduct of Clinical Trials during the COVID-19 lockdown
- Emergency use of Remdesivir in the context of the Covid-19 Pandemic
- Pharmacovigilance requirements for Remdesivir products under emergency importation
- Requirement for a Pharmacovigilance system for licensed persons in Uganda
- Provisions for emergency importation of Remdesivir in the context of the COVID-19 Pandemic
- Communication circular on Clinical Trial new format for CT certificates
- Adulterated Herbal products on the market
- Caution against stockpiling and irrational use of medicine
- Certification of premises used to supply restricted drugs within institutions conducting clinical trials
- Presence of a potentially genotoxic impurity, N-nitrosodimethylamine (NDMA) in Ranitidine
- Circular on Importation, Exportation & sale of Chloroquine & Hydroxychloroquine
- Increased risk of non-melanoma skin cancer associated with HCTZ
- Clarification on Hydrochlorothiazide
- Furosemide injection manufactured by Grand pharmaceutical (china) co., ltd; batch number 180120
- Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics
- Risk of crystalization of Mannitol 20% iv solution
- Recall of Valsartan a drug used in the treatment of high blood pressure
- Gentamycin Injection
- Risk of drug interactions and side effects due to use of herbal remedies – Anticancer Treatment
- Notice to cease purchase and use of Rabicid-iv (Rabeprazole injection ip)
- Risk of hypersensitivity reaction in infants and children following administration of Nevirapine
- Increased risk of otoxicity following concomitant administration of Gentamicin and Furosemide
- Mandatory Post Shipment Circular
- Circular on Unaunthorised Medical Devices on the Ugandan Market
- Circular on Importation of Healthcare Products for surgical / medical/ dental camps
- Adulterated L-power coffee supplied by Liven Global SDN. BHD – Malaysia
- Circular on importation and distribution of Hypodermic Syringes and Needles
- Signposts for drug outlets
- WHO Global alert on substandard (contaminated) pediatric cough syrups identified in Gambia – West Africa
- Ban on the use Chloroform (Trichloromethane) in Pharmaceutical preparations
- Labelling requirements for surgical sutures
- Revision of National Drug Authority professional Guidelines for Variations of Registered products
- Retention of products on the register for the financial year 2025/2026
- Clarification on fees payable for post approval amendments (variations) applications affecting multiple products
- Withdraw of marketing authorization for Ketoconazole oral Tablets
- Circular No. 01-DPAR-2024_Submission of Vet Pharma Product Dossiers in CTD Format
